A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2002
08/13/2002	US6433022 Exposure of semen to naphthoquinone/1,4-/ or juglone; reduction to semiquinone and generation of oxygen, superoxide, hydrogen peroxide, or free radicals; immobilization
08/13/2002	US6433018 Method for reducing hypertrophy and ischemia
08/13/2002	US6432996 Pharmaceutical composition
08/13/2002	US6432989 Use of CRF antagonists to treat circadian rhythm disorders
08/13/2002	US6432986 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
08/13/2002	US6432972 Desloratadine as non-sedating antihistamine, decongestant
08/13/2002	US6432966 Antiviral combinations
08/13/2002	US6432962 Antiinflammatory agents
08/13/2002	US6432945 Dipeptide derivatives
08/13/2002	US6432935 Synergistic mixture of antibiotic, sulfadimidine and fungicide
08/13/2002	US6432929 Cartilage enhancing food supplements and methods of preparing the same
08/13/2002	US6432918 Methods and compositions for optimization of oxygen transport by cell-free systems
08/13/2002	US6432703 Isolated polynucleotide sequences
08/13/2002	US6432687 Polypeptide amino acid sequence with immunoactive segments
08/13/2002	US6432667 Polynucleotide encoding TIE-2 ligand-4
08/13/2002	US6432659 Motor proteins and methods for their use
08/13/2002	US6432449 Anionic polysaccharides coupled with a metal and a complex leptin protein; biocompatible injections having no side effects
08/13/2002	US6432409 Hybrid peptides modulate the immune response
08/13/2002	US6432401 Administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist; use in hair graft procedures, for example
08/13/2002	US6431874 Stop smoking method and composition
08/12/2002	CA2370236A1 Method for inhibiting retinoid skin damage
08/08/2002	WO2002061046A2 Novel nucleic acid and polypeptide molecules
08/08/2002	WO2002060955A2 Modified antibodies and methods of use
08/08/2002	WO2002060950A2 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
08/08/2002	WO2002060942A2 Protein modification and maintenance molecules
08/08/2002	WO2002060900A2 Antagonists of mcp-1 function and methods of use thereof
08/08/2002	WO2002060894A2 Sulfonamide lactam inhibitors of factor xa
08/08/2002	WO2002060879A2 Bacterial gyrase inhibitors and uses thereof
08/08/2002	WO2002060869A2 Use of p38 inhibitors for the treatment of inflammation-enhanced cough
08/08/2002	WO2002060863A1 Ophthalmic compositions for treating ocular hypertension
08/08/2002	WO2002060501A2 Hydrogel wound dressing,preparation and use thereof
08/08/2002	WO2002060491A2 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman
08/08/2002	WO2002060489A1 Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing
08/08/2002	WO2002060485A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders
08/08/2002	WO2002060484A1 Use of cd23 antagonists for the treatment of neoplastic disorders
08/08/2002	WO2002060482A2 Perylenequinones for use with immunotherapy agents
08/08/2002	WO2002060480A1 Methods for treating or preventing skin disorders using cd2-binding agents
08/08/2002	WO2002060479A1 Use of il-18 inhibitors for the treatment and/or prevention of heart disease
08/08/2002	WO2002060474A2 Mixtures of mushroom enzymes and the use thereof for treating maldigestion
08/08/2002	WO2002060460A1 Remedies for cancer
08/08/2002	WO2002060459A2 Use of iodide salt as an aphrodisiac
08/08/2002	WO2002060454A2 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
08/08/2002	WO2002060453A1 Remedies for lung cancer
08/08/2002	WO2002060437A1 Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
08/08/2002	WO2002060434A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
08/08/2002	WO2002060427A2 Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
08/08/2002	WO2002060425A1 Methods and compositions for treating addiction disorders
08/08/2002	WO2002060424A2 Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
08/08/2002	WO2002060423A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
08/08/2002	WO2002060422A2 Treatment of diabetes mellitus using vardenafil
08/08/2002	WO2002060419A2 A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
08/08/2002	WO2002060412A2 Stabilised polymeric aerosols for pulmonary gene delivery
08/08/2002	WO2002060393A2 Proteoglycan compositions for treatment of inflammatory conditions
08/08/2002	WO2002060388A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
08/08/2002	WO2002060386A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
08/08/2002	WO2002060383A2 Cancer therapy
08/08/2002	WO2002060378A2 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
08/08/2002	WO2002060339A2 Ophthalmic compositions for treating ocular hypertension
08/08/2002	WO2002040505A3 Dibenzoxazepine alpha v integrin receptor antagonist
08/08/2002	WO2002034903A3 Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications
08/08/2002	WO2002032900A3 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
08/08/2002	WO2002030455A3 Agents for the treatment of viral infections
08/08/2002	WO2002026192A3 Viruses targeted to hypoxic cells and tissues
08/08/2002	WO2002024650A3 Pyridinone and pyridinethione derivatives having hiv inhibiting properties
08/08/2002	WO2002022175A3 Method and composition for treating tumors by selective induction of apoptosis
08/08/2002	WO2002022161A3 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases
08/08/2002	WO2002015722A3 Treatment of helicobacter with isothiocyanates
08/08/2002	WO2002011735A3 Association of a purine activity and a nonsteroidal anti-inflammatory anti-inflammatory drug for treating sexual dysfunction
08/08/2002	WO2002011665A3 Association of a purine and a nonsteroidal anti-inflammatory drug for treating sexual dysfunction
08/08/2002	WO2002009690A3 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
08/08/2002	WO2002005851A3 Enhancement of the action of central and peripheral nervous system agents
08/08/2002	WO2002002744A3 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
08/08/2002	WO2002000840A3 Human lyases
08/08/2002	WO2002000170A3 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
08/08/2002	WO2001096546A3 Protein phosphatases
08/08/2002	WO2001093840A3 Ligands of integrin receptors
08/08/2002	WO2001092306A3 Therapeutic compounds for ovarian cancer
08/08/2002	WO2001090330A3 AMINOACYL tRNA SYNTHETASES
08/08/2002	WO2001085664A3 Compounds and methods for regulating bacterial growth and pathogenesis
08/08/2002	WO2001085150A3 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
08/08/2002	WO2001081585A3 A thymus expressed human cytochrome p450 (p450tec)
08/08/2002	WO2001081312A3 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
08/08/2002	WO2001080895A3 Methods and compositions for the treatment of cardiac indications
08/08/2002	WO2001080890A3 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
08/08/2002	WO2001070941A3 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
08/08/2002	WO2001070211A3 L-arginine and phosphodiesterase (pde) inhibitor synergism
08/08/2002	WO2001056555A3 Use of cox-2 inhibitors for the treatment of constipation
08/08/2002	WO2001051641A9 Irak-4: compositions and methods of use
08/08/2002	WO2001051523A3 Anti-angiogenic proteins and fragments and methods of use thereof
08/08/2002	WO2001048238A3 Chemotherapeutant screening method
08/08/2002	WO2001032925A9 Modulation of neuroendocrine differentiation by protein 25.1
08/08/2002	WO2001027635A9 Multiwell scanner and scanning method
08/08/2002	WO2001021799A9 Traf4 associated cell cycle proteins, compositions and methods of use
08/08/2002	WO2001009328A9 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
08/08/2002	US20020107385 Human breast tumor-specific proteins
08/08/2002	US20020107370 Protein for use in the treatment of lzheimer's, parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, retinopathy, brain, blood, myocardium, stroke, reperfusion injury and liver disorders
08/08/2002	US20020107368 Helicobacter proteins, gene sequences and uses thereof
08/08/2002	US20020107363 B7-Like molecules and uses thereof
08/08/2002	US20020107361 Novel metalloproteases having thrombospondin domains and nucleic acid compositions encoding the same
08/08/2002	US20020107359 Protein model for use in drug design in human therapeutics

1 ... 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 ... 1151